Logo image of ECT.AS

EUROCASTLE INVESTMENT LTD (ECT.AS) Stock Overview

Europe - AMS:ECT - GB00B94QM994

9.4 EUR
+0.2 (+2.17%)
Last: 9/17/2025, 7:00:00 PM
Fundamental Rating

4

ECT gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 74 industry peers in the Real Estate Management & Development industry. ECT is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. ECT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year ECT was profitable.
ECT had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: ECT reported negative net income in multiple years.
ECT had a negative operating cash flow in each of the past 5 years.
ECT.AS Yearly Net Income VS EBIT VS OCF VS FCFECT.AS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

1.2 Ratios

With a Return On Assets value of 1.54%, ECT perfoms like the industry average, outperforming 55.41% of the companies in the same industry.
The Return On Equity of ECT (1.57%) is comparable to the rest of the industry.
With a Return On Invested Capital value of 1.17%, ECT perfoms like the industry average, outperforming 47.30% of the companies in the same industry.
Industry RankSector Rank
ROA 1.54%
ROE 1.57%
ROIC 1.17%
ROA(3y)-1.72%
ROA(5y)-1.28%
ROE(3y)-1.77%
ROE(5y)-1.34%
ROIC(3y)N/A
ROIC(5y)N/A
ECT.AS Yearly ROA, ROE, ROICECT.AS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40

1.3 Margins

ECT has a Profit Margin of 28.98%. This is in the better half of the industry: ECT outperforms 71.62% of its industry peers.
ECT's Profit Margin has been stable in the last couple of years.
Looking at the Operating Margin, with a value of 28.98%, ECT is in line with its industry, outperforming 56.76% of the companies in the same industry.
In the last couple of years the Operating Margin of ECT has remained more or less at the same level.
ECT's Gross Margin of 91.37% is amongst the best of the industry. ECT outperforms 85.14% of its industry peers.
ECT's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 28.98%
PM (TTM) 28.98%
GM 91.37%
OM growth 3Y-7.21%
OM growth 5Y-1.26%
PM growth 3Y-7.21%
PM growth 5Y-1.2%
GM growth 3Y-0.87%
GM growth 5Y19.91%
ECT.AS Yearly Profit, Operating, Gross MarginsECT.AS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200 -300

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for ECT has been increased compared to 1 year ago.
ECT has less shares outstanding than it did 5 years ago.
ECT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ECT.AS Yearly Shares OutstandingECT.AS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ECT.AS Yearly Total Debt VS Total AssetsECT.AS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

ECT has an Altman-Z score of -85.74. This is a bad value and indicates that ECT is not financially healthy and even has some risk of bankruptcy.
ECT has a Altman-Z score of -85.74. This is amonst the worse of the industry: ECT underperforms 91.89% of its industry peers.
There is no outstanding debt for ECT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -85.74
ROIC/WACCN/A
WACCN/A
ECT.AS Yearly LT Debt VS Equity VS FCFECT.AS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M 500M

2.3 Liquidity

A Current Ratio of 27.47 indicates that ECT has no problem at all paying its short term obligations.
ECT has a Current ratio of 27.47. This is amongst the best in the industry. ECT outperforms 97.30% of its industry peers.
A Quick Ratio of 27.47 indicates that ECT has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 27.47, ECT belongs to the best of the industry, outperforming 97.30% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 27.47
Quick Ratio 27.47
ECT.AS Yearly Current Assets VS Current LiabilitesECT.AS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 154.32% over the past year.
Measured over the past years, ECT shows a decrease in Earnings Per Share. The EPS has been decreasing by -2.08% on average per year.
Looking at the last year, ECT shows a very strong growth in Revenue. The Revenue has grown by 153.50%.
Measured over the past years, ECT shows a very negative growth in Revenue. The Revenue has been decreasing by -52.85% on average per year.
EPS 1Y (TTM)154.32%
EPS 3Y-15.5%
EPS 5Y-2.08%
EPS Q2Q%322.22%
Revenue 1Y (TTM)153.5%
Revenue growth 3Y-25.89%
Revenue growth 5Y-52.85%
Sales Q2Q%185.29%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ECT.AS Yearly Revenue VS EstimatesECT.AS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M
ECT.AS Yearly EPS VS EstimatesECT.AS Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 0 1 2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ECT is valuated quite expensively with a Price/Earnings ratio of 26.86.
The rest of the industry has a similar Price/Earnings ratio as ECT.
The average S&P500 Price/Earnings ratio is at 27.41. ECT is around the same levels.
Industry RankSector Rank
PE 26.86
Fwd PE N/A
ECT.AS Price Earnings VS Forward Price EarningsECT.AS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ECT.AS Per share dataECT.AS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15 20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ECT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EUROCASTLE INVESTMENT LTD

AMS:ECT (9/17/2025, 7:00:00 PM)

9.4

+0.2 (+2.17%)

Chartmill FA Rating
GICS SectorReal Estate
GICS IndustryGroupEquity Real Estate Investment Trusts (REITs)
GICS IndustryReal Estate Management & Development
Earnings (Last)08-05 2025-08-05
Earnings (Next)N/A N/A
Inst Owners5.57%
Inst Owner ChangeN/A
Ins Owners3.77%
Ins Owner ChangeN/A
Market Cap9.40M
Analysts84
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 26.86
Fwd PE N/A
P/S 7.87
P/FCF N/A
P/OCF N/A
P/B 0.43
P/tB 0.43
EV/EBITDA N/A
EPS(TTM)0.35
EY3.72%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-5.78
FCFYN/A
OCF(TTM)-5.78
OCFYN/A
SpS1.19
BVpS22.09
TBVpS22.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 1.54%
ROE 1.57%
ROCE 1.57%
ROIC 1.17%
ROICexc 2.68%
ROICexgc 4.82%
OM 28.98%
PM (TTM) 28.98%
GM 91.37%
FCFM N/A
ROA(3y)-1.72%
ROA(5y)-1.28%
ROE(3y)-1.77%
ROE(5y)-1.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-7.21%
OM growth 5Y-1.26%
PM growth 3Y-7.21%
PM growth 5Y-1.2%
GM growth 3Y-0.87%
GM growth 5Y19.91%
F-Score5
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 27.47
Quick Ratio 27.47
Altman-Z -85.74
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)154.32%
EPS 3Y-15.5%
EPS 5Y-2.08%
EPS Q2Q%322.22%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)153.5%
Revenue growth 3Y-25.89%
Revenue growth 5Y-52.85%
Sales Q2Q%185.29%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y154.49%
EBIT growth 3Y-31.23%
EBIT growth 5Y-53.45%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-52.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-52.2%
OCF growth 3YN/A
OCF growth 5YN/A